Novel immunomodulatory enzymes for transplantation and acute autoimmune diseases

Hansa Biopharma is focused on developing innovative immunomodulating therapies aimed at transforming the lives of individuals affected by rare immunologic diseases. The company's proprietary technologies, particularly the antibody-cleaving enzymes imlifidase and HNSA-5487, are designed to target and inactivate IgG antibodies in the blood and tissues. This mechanism helps to inhibit IgG-mediated immune responses, which can be detrimental in conditions such as acute autoimmune diseases and in facilitating life-saving procedures like organ transplantation. Hansa's approach addresses significant unmet medical needs, particularly in highly sensitized kidney transplant patients and other autoimmune disorders.

The company is advancing its clinical pipeline through various phases of research, including ongoing studies for imlifidase in kidney transplantation and HNSA-5487 in multiple indications. Hansa has received conditional approval for imlifidase in the European Union, with plans for post-approval studies to further validate its efficacy. Additionally, Hansa is exploring the potential of its therapies in gene therapy enablement, aiming to enhance treatment options for genetic disorders. Through rigorous clinical trials and a commitment to regulatory compliance, Hansa Biopharma is dedicated to ensuring that its innovative therapies reach patients who need them most, ultimately striving to improve patient outcomes in the realm of rare immunologic conditions.

Sweden

Hansa Biopharma, is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative and life altering treatments for patients with rare immunological conditions.

Hansa scientists are working on developing immunomodulatory treatments for organ transplants, rare IgG-mediated autoimmune conditions, and gene therapy, as well as exploring the potential application of the technology platform in oncology.

Hansa Biopharma

Company Details